Dr. Shapiro’s work has appeared in a wide range of peer-reviewed journals. Below is a selection of some recent publications.

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (ulixertinib). Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ. Mol Cancer Ther. 2017 Sep 22. pii: molcanther.0456.2017. doi: 10.1158/1535-7163.MCT-17-0456. [Epub ahead of print] PMID:28939558

Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells. Li Z, Li D, Choi EY, Lapidus R, Zhang L, Huang SM, Shapiro P, Wang H. J Biol Chem. 2017 Aug 18;292(33):13890-13901. doi: 10.1074/jbc.M117.783860. Epub 2017 Jun 27. PMID:28655760

Novel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity. Shah NG, Tulapurkar ME, Ramarathnam A, Brophy A, Martinez R 3rd, Hom K, Hodges T, Samadani R, Singh IS, MacKerell AD Jr, Shapiro P, Hasday JD. J Immunol. 2017 Apr 15;198(8):3296-3306. doi: 10.4049/jimmunol.1602059. Epub 2017 Mar 15. PMID:28298524

Samadani R, Zhang J, Brophy A, Oashi T, Priyakumar UD, Raman EP, St John FJ, Jung KY, Fletcher S, Pozharski E, MacKerell AD, Shapiro PS (2015) Small Molecule Inhibitors of ERK-mediated Immediate Early Gene Expression and Proliferation of Melanoma Cells Expressing Mutated BRaf. Biochem J. Volume 467 (part 3), p425-438. PMID: 25695333

Jung, K.-Y., Samadani, R., Chauhan, J., Nevels, K., Yap, J. L., Zhang, J., Worlikar, S., Lanning, M. E., Chen, L., Ensey, M., Shukla, S., Salmo, R., Heinzl, G., Gordon, C., Dukes, T., MacKerell, Jr., A. D., Shapiro, P.* and Fletcher, S.* (2013). Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling. Organic & Biomolecular Chemistry, DOI:10.1039/C3OB40199E. *(co-corresponding authors)

Jun Zhang, Paul Shapiro and Edwin Pozharski, (2012) Structure of extracellular signal-regulated kinase 2 in complex with ATP and ADP. Acta Crystallographica Section F: Structural Biology and Crystallization Communications, Volume 68, Part 12, pages 1434-1439. PMID:23192020

Burkhard KA, Chen F, Shapiro P. (2011) Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity. J Biol Chem. Jan 28;286(4):2477-85. PMID: 21098038

Boston SR, Deshmukh R, Strome S, Priyakumar UD, Mackerell AD Jr, Shapiro P. (2011) Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9. BMC Cancer. Jan 10;11(1):7. [Epub ahead of print] PMID: 21219631

Dai B, Zhao XF, Mazan-Mamczarz K, Hagner P, Corl S, Bahassi EM, Lu S, Stambrook PJ, Shapiro P, Gartenhaus, RB. (2011) Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nature Communications, 2:402, published July 19, 2011. PMID:21772273

Barr D, Oashi T, Burkhard K, Lucius S, Samadani R, Zhang J, Shapiro P*, MacKerell Jr. AD*, van der Vaart A*(2011) The importance of domain closure for the auto-activation of ERK2. Biochemistry. Sep 20;50(37):8038-48. PMID:21842857